About: Meeting report: 27th International conference on antiviral research, in Raleigh, NC, USA

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Meeting report: 27th International conference on antiviral research, in Raleigh, NC, USA Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Meeting report: 27th International conference on antiviral research, in Raleigh, NC, USA
Creator	Anthony, R Hodge, Vere
Source	Elsevier; Medline; PMC
abstract	The 27th International Conference on Antiviral Research (ICAR) was held in Raleigh, North Carolina, USA from May 12 to 16, 2014. This article summarizes the principal invited lectures. John Drach (Elion Award) described the early days of antiviral drugs and their novel modes of action. Piet Herdewijn (Holý Award) used evolutionary pressure to select DNA polymerases that accept nucleoside analogs. Replacing thymine by 5-chlorouracil led to the generation of a new form of Escherichia coli. Adrian Ray (Prusoff Award) demonstrated how prodrugs can markedly improve both the efficacy and safety of potential drugs. The keynote addresses, by David Margolis and Myron Cohen, tackled two emerging areas of HIV research, to find an HIV “cure” and to prevent HIV transmission, respectively. These topics were discussed further in other presentations – a cure seems to be a distant prospect but there are exciting developments for reducing HIV transmission. TDF-containing vaginal rings and GSK-744, as a long-lasting injection, offer great hope. There were three mini-symposia. Although therapy with TDF/FTC gives excellent control of HBV replication, there are only a few patients who achieve a functional cure. Myrcludex, an entry inhibitor, is active against both HBV and HDV. The recent progress with HBV replication in cell cultures has transformed the search for new antiviral compounds. The HBV capsid protein has been recognized as key player in HBV DNA synthesis. Unexpectedly, compounds which enhance capsid formation, markedly reduce HBV DNA synthesis. The development of BCX4430, which is active against Marburg and Ebola viruses, is of great current interest.
has issue date	2014-09-16(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2014.08.009
bibo:pmid	25218950
has license	no-cc
sha1sum (hex)	1ee67f3e602c1d0ef993fecb7ddfe993bbe5ef23
schema:url	https://doi.org/10.1016/j.antiviral.2014.08.009
resource representing a document's title	Meeting report: 27th International conference on antiviral research, in Raleigh, NC, USA
has PubMed Central identifier	PMC7119014
has PubMed identifier	25218950
schema:publication	Antiviral Res
resource representing a document's body	covid:1ee67f3e602c1d0ef993fecb7ddfe993bbe5ef23#body_text
is schema:about of	named entity 'RESEARCH' named entity 'MEETING REPORT' named entity 'USA' named entity 'RALEIGH' named entity 'ANTIVIRAL' named entity 'INTERNATIONAL CONFERENCE' named entity 'David Margolis' named entity 'virological' named entity 'HDV' named entity 'viral load' named entity 'HIV transmission' named entity 'proof-of-concept' named entity 'hepatic' named entity 'cell culture assays' named entity 'HIV' named entity 'infection' named entity 'HBsAg' named entity 'nucleotide analog' named entity 'HIV' named entity 'viremia' named entity 'protein' named entity 'discovery program' named entity 'ganciclovir' named entity 'drug molecules' named entity 'infective agent' named entity 'Gilead' named entity 'thymine' named entity 'HBV' named entity 'organ rejection' named entity 'HBV' named entity 'protein' named entity 'HBV' named entity 'HBV' named entity 'lactic acidosis' named entity 'BCX4430' named entity 'human herpesvirus 8' named entity 'infection' named entity 'sofosbuvir' named entity 'nucleotide' named entity 'Antiviral Research' named entity 'HBV' named entity 'clinical trial' named entity 'genomic replication' named entity 'nucleoside' named entity 'Duke University' named entity 'Phase II trials' named entity 'virus' named entity 'HIV-infected patients' named entity 'antiretroviral therapy' named entity 'Myron Cohen' named entity 'HBeAg' named entity 'RNA' named entity 'PrEP' named entity 'RNA' named entity 'HBV' named entity 'safer-sex' named entity 'Research Triangle Park' named entity 'HIV' named entity 'HSV-1' named entity 'Ebola epidemic' named entity 'Stribild' named entity 'HCMV' named entity 'HIV' named entity 'protein' named entity 'University of North Carolina' named entity 'clinical trials' named entity 'WHV' named entity 'phosphorylated' named entity 'E. coli' named entity 'HIV transmission' named entity 'valganciclovir' named entity 'New York City' named entity 'capsid' named entity 'ICAR' named entity 'HIV' named entity 'Germany' named entity 'HBV' named entity 'contraceptive devices' named entity 'animal model' named entity 'epithelial cells'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software